Clinical Trial: Phase 1 Open-label Study of AMX-883 Alone in Participants With AML and High-risk MDS and in Combination in Participants With AML

U.S., July 24 -- ClinicalTrials.gov registry received information related to the study (NCT07723703) titled 'Phase 1 Open-label Study of AMX-883 Alone in Participants With AML and High-risk MDS and in Combination in Participants With AML' on July 20.

Brief Summary: The purpose of the study is to assess the safety, pharmacokinetics, and preliminary efficacy of AMX-883 monotherapy in participants with acute myeloid leukaemia (AML) and high-risk myelodysplastic syndrome (MDS) and in combination with anticancer agents in participants with AML.

Study Start Date: Sept. 01

Study Type: INTERVENTIONAL

Condition: Acute Myeloid Leukaemia High Risk Myelodysplastic Syndrome

Intervention: DRUG: AMX-883

AMX-883 will be administered orally.

DRUG: ...